StemRIM
StemrIM Co., Ltd. 2026 July Term Financial Results Summary (Japan GAAP) (Consolidated)
For the July 2026 period, on a consolidated basis, operating loss of △1,998 million yen and net loss attributable to owners of the parent of △1,851 million yen were recorded. Because the business model heavily depends on milestone revenue, earnings guidance for the 2027 period has not been disclosed. Development of regenerative medicine focused on redacetamid is continuing. Although cash and cash equivalents declined significantly versus the previous period, development funding through 2028 is secured. An earnings briefing material and an investor/analyst briefing are planned.
Key Figures
- Pre-tax loss for the period: △1,849,546 thousand yen
- Net loss for the period (△): △1,851,498 thousand yen
- Ending balance of cash and cash equivalents: 2,177,035 thousand yen
AI要約
Overview of results
This period's consolidated results do not disclose net sales; ordinary loss was △1,879 million yen and net loss attributable to owners of the parent was △1,851 million yen. Given the business model's heavy reliance on milestone revenue, a rational earnings forecast for the July 2027 period is considered difficult to calculate and is not disclosed at this time. R&D expenses are increasing, with continued costs related to the development of redanosmitide. Cash and cash equivalents declined significantly, but development funds through 2028 are secured. An earnings briefing document and an IR/analyst briefing are planned.
Outlook and capital position
The 2027 July period earnings forecast will not be disclosed; ongoing progress in the development of a leading regenerative medicine around redanosmitide and licensing negotiations are expected to continue. Although cash has declined significantly, assume R&D expenses of 1,300 million yen to 1,700 million yen and SG&A of 230 million yen to 310 million yen, and continue securing funding through 2038. Note that upfront payments from new alliances and the timing of milestone revenue are uncertain.
StemrIM Co., Ltd.
Company overview · Stock price · Financial data · All IR
